Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

261
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
261
Hepatic Portal System01:21

Hepatic Portal System

5.6K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.6K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

219
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
219
Fats as Energy Storage Molecules01:06

Fats as Energy Storage Molecules

26.9K
Triglycerides are a form of long-term energy storage molecules. They are made of glycerol and three fatty acids. To obtain energy from fat, triglycerides must first be broken down by hydrolysis into their two principal components, fatty acids and glycerol. This process, called lipolysis, takes place in the cytoplasm. The resulting fatty acids are oxidized by β-oxidation into acetyl-CoA, which is used by the Krebs cycle. The glycerol that is released from triglycerides after lipolysis...
26.9K
Defenses Against Pathogens and Herbivores02:26

Defenses Against Pathogens and Herbivores

29.5K
Plants present a rich source of nutrients for many organisms, making it a target for herbivores and infectious agents. Plants, though lacking a proper immune system, have developed an array of constitutive and inducible defenses to fend off these attacks.
29.5K
Defense Against Bacterial Pathogens01:31

Defense Against Bacterial Pathogens

2.7K
The human immune system is a complex network of cells, tissues, and organs that work together to defend the body against bacterial infections. It consists of various immune cells, each playing a specific role in the defense mechanism.
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of primary care in response to the global liver disease syndemic: a Lancet Gastroenterology & Hepatology Commission.

The lancet. Gastroenterology & hepatology·2026
Same author

Management of Metabolic Dysfunction-Associated Steatotic Liver Disease with Lifestyle Modification.

Clinics in liver disease·2026
Same author

Global Structural Determinants of MASLD: Development-Stratified Pathways Linking Food Systems, Metabolic Risk, and Liver Outcomes.

JHEP reports : innovation in hepatology·2026
Same author

Implementing sustainable liver health in Europe: a second EASL-Lancet Commission.

Lancet (London, England)·2026
Same author

From science to public health impact: Enacting the recommendations of the EASL-Lancet Commission on liver health in Europe.

Journal of hepatology·2026
Same author

Dynamics of Body Composition and Metabolic Risk in Adolescents With Obesity Under GLP-1 Receptor Agonist Therapy.

Acta paediatrica (Oslo, Norway : 1992)·2026
Same journal

Reply to "Role of HBV genotype, monitoring, and events after cessation of nucleos(t)ide analogue therapy".

Journal of hepatology·2026
Same journal

When Biology Pushes Back: Lessons From HBsAg-Targeting Therapies in Hepatitis Delta.

Journal of hepatology·2026
Same journal

Moving Too Fast? A Meta-Analysis Calls for Caution on TNF Inhibitors as First-Line Therapy for Autoimmune Hepatitis.

Journal of hepatology·2026
Same journal

Anserine restores antibacterial immunity in cirrhosis via a protective CCL5-mediated hepatocyte-CD44<sup>+</sup>pDC crosstalk.

Journal of hepatology·2026
Same journal

Anti-CCL2-conjugated platelets attenuate early allograft and ischemia-reperfusion injury by inhibiting monocyte infiltration.

Journal of hepatology·2026
Same journal

A precision randomized trial of hepatitis C treatment support among people who inject drugs in India: The STOP-C Trial.

Journal of hepatology·2026
See all related articles

Related Experiment Video

Updated: Jan 23, 2026

Assay for Pathogen-Associated Molecular Pattern PAMP-Triggered Immunity PTI in Plants
08:45

Assay for Pathogen-Associated Molecular Pattern PAMP-Triggered Immunity PTI in Plants

Published on: September 9, 2009

27.8K

Hepatic fat: Pathogenic trigger or passenger?

Marno C Ryan1, Shira Zelber-Sagi2

  • 1University of Melbourne St Vincent's Hospital, Fitzroy, Australia.

Journal of Hepatology
|June 23, 2019
PubMed
Summary

No abstract available in PubMed .

Keywords:
Cardiovascular diseasesDietFatty liverInsulin resistanceMediterranean

More Related Videos

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

3.4K
Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.6K

Related Experiment Videos

Last Updated: Jan 23, 2026

Assay for Pathogen-Associated Molecular Pattern PAMP-Triggered Immunity PTI in Plants
08:45

Assay for Pathogen-Associated Molecular Pattern PAMP-Triggered Immunity PTI in Plants

Published on: September 9, 2009

27.8K
Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

3.4K
Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.6K